학술논문
Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study
Document Type
Author abstract
Author
Source
The Lancet. August 3, 2013, Vol. 382 Issue 9890, p409, 8 p.
Subject
Language
English
ISSN
0140-6736
Abstract
Guidelines suggest setting individualised targets for glycaemic control in elderly patients with type 2 diabetes, despite no evidence. We aimed to assess the feasibility of setting and achieving individualised targets over 24 weeks along with conventional HbA.sub.1c reduction using vildagliptin versus placebo.